Pharmaceutical company Dr. Reddy's Laboratories Ltd., which has offices in Princeton, New Jersey, completed the acquisition of select portfolio of established brands of Belgian firm UCB in India.

Dr. Reddy’s has said the acquired UCB portfolio would accelerate its presence in the high growth areas of dermatology, respiratory and pediatrics, with brands such as Atarax, Nootropil, Zyrtec, Xyzal and Xyzal M. The company originally announced in April that it would acquire select portfolio of established brands of UCB in India, Nepal, Sri Lanka and Maldives for Rs. 800 crore ($130 million).

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.